EMEA-002765-PIP02-21
Key facts
| Invented name |
Kisqali
|
| Active substance |
Ribociclib
|
| Therapeutic area |
Oncology
|
| Decision number |
P/0020/2022
|
| PIP number |
EMEA-002765-PIP02-21
|
| Pharmaceutical form(s) |
|
| Condition(s) / indication(s) |
Treatment of neuroblastoma
|
| Route(s) of administration |
Oral use
|
| Contact for public enquiries |
Novartis Europharm Limited
Tel. +41 6132 41111 |
| Decision type |
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
|